Vivesto AB (OASMY)
Vivesto AB operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Solna, MD, SE. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $20,606. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 1.75 implies it has historically moved more than the broad market.
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
Vivesto AB is most often compared with the following Healthcare names: